*** IBB - CNR *** Department of Advanced Biomedical Sciences, Section of Cardiology, Federico II University, Naples,Italy. Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Institute of Telese Terme, Telese Terme (BN), Italy Department of Translational Medical Sciences, Section of Geriatrics, Federico II University, Naples, Italy Institute of Biostructures, Bioimages of the National Council of Research, Naples, Italy Department of Cardiology, Fatebenefratelli Hospital, Naples, Italy Department of Molecular Medicine and Medical Biotechnologies, Federico II University, Naples, Italy SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy
Riferimenti:
Rengo, G., Lymperopoulos, A., Leosco, D., Koch, W.J., GRK2 as a novel gene therapy target in heart failure (2011) J Mol Cell Cardiol, 50, pp. 785-79
Lymperopoulos, A., Rengo, G., Koch, W.J., Adrenal adrenoceptors in heart failure: Fine-tuning cardiac stimulation (2007) Trends Mol Med, 13, pp. 503-511
Rengo, G., Perrone-Filardi, P., Femminella, G.D., Targeting the b-adrenergic receptor system through G-protein-coupled receptor kinase 2: A new paradigm for therapy and prognostic evaluation in heart failure: From bench to bedside (2012) Circ Heart Fail, 5, pp. 385-391
Pilotto, A., Addante, F., Franceschi, M., Multidimensional prognostic index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure (2010) Circ Heart Fail, 3, pp. 14-20
Rengo, G., Zincarelli, C., Femminella, G.D., Myocardial b(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure (2012) Br J Pharmacol, 166, pp. 2348-2361
Jacobson, A.F., Senior, R., Cerqueira, M.D., Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIREHF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study (2010) J Am Coll Cardiol, 55, pp. 2212-2221. , ADMIRE-HF Investigators
Langer, A., Freeman, M.R., Josse, R.G., Armstrong, P.W., Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia (1995) JAmCollCardiol, 25, pp. 610-618
Yufu, K., Takahashi, N., Okada, N., Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease (2012) Circ J, 76, pp. 399-404
Soläng, L., Malmberg, K., Rydén, L., Diabetes mellitus and congestive heart failure. Further knowledge needed (1999) Eur Heart J, 20, pp. 789-795
Ho, K.K., Anderson, K.M., Kannel, W.B., Grossman, W., Levy, D., Survival after the onset of congestive heart failure in Framingham Heart Study subjects (1993) Circulation, 88, pp. 107-115
Shindler, D.M., Kostis, J.B., Yusuf, S., Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry (1996) Am J Cardiol, 77, pp. 1017-1020
Gerson, M.C., Caldwell, J.H., Ananthasubramaniam, K., Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients (2011) Circ Cardiovasc Imaging, 4, pp. 87-93
Rydén, L., Standl, E., Bartnik, M., Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary (2007) Eur Heart J, 28, pp. 88-136. , Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC)
European Association for the Study of Diabetes (EASD)
Levey, A.S., Coresh, J., Balk, E., National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (2003) Ann Intern Med, 139, pp. 137-147. , National Kidney Foundation
Standards of medical care in diabetesd2012 (2012) Diabetes Care, 35 (SUPPL. 1), pp. S11-S63. , American Diabetes Association
Moghtaderi, A., Bakhshipour, A., Rashidi, H., Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy (2006) Clin Neurol Neurosurg, 108, pp. 477-481
Lang, R.M., Bierig, M., Devereux, R.B., Recommendations for chamber quantification (2006) Eur J Echocardiogr, 7, pp. 79-108. , American Society of Echocardiography's Nomenclature and Standards Committee
Task Force on Chamber Quantification
American College of Cardiology Echocardiography Committee
AmericanHeart Association
Pace, L., Perrone-Filardi, P., Mainenti, P., Identification of viable myocardium in patients with chronic coronary artery disease using rest-redistribution thallium-201 tomography: Optimal image analysis (1998) J Nucl Med, 39, pp. 1869-1874
Flotats, A., Carrió, I., Agostini, D., Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology (2010) Eur J Nucl Med Mol Imaging, 37, pp. 1802-1812. , EANM Cardiovascular Committee
Ewing, D.J., Martyn, C.N., Young, R.J., Clarke, B.F., The value of cardiovascular autonomic function tests: 10 years experience in diabetes (1985) Diabetes Care, 8, pp. 491-498
Scholte, A.J., Schuijf, J.D., Delgado, V., Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: Comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability (2010) Eur J Nucl Med Mol Imaging, 37, pp. 1698-1705
Scherrer, U., Sartori, C., Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity (1997) Circulation, 96, pp. 4104-4113
Kreiner, G., Wolzt, M., Fasching, P., Myocardial m-[123I] iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function (1995) Diabetes, 44, pp. 543-549
Scognamiglio, R., Avogaro, A., Casara, D., Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetesmellitus (1998) J Am Coll Cardiol, 31, pp. 404-412
Ziegler, D., Weise, F., Langen, K.J., Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I] metaiodobenzylguanidine scintigraphy: A 4-year prospective study in IDDM patients (1998) Diabetologia, 41, pp. 443-451
Toyama, T., Aihara, Y., Iwasaki, T., Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after betablocker or angiotensin- converting enzyme inhibitor therapy (1999) J Nucl Med, 40, pp. 217-223
Boogers, M.J., Borleffs, C.J., Henneman, M.M., Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients (2010) J Am Coll Cardiol, 55, pp. 2769-2777
OBJECTIVE: Impaired parasympathetic and sympathetic nervous system activity have been demonstrated in patients with diabetes mellitus (DM) and correlated with worse prognosis. Few data are available on the effect of DM on cardiac neuropathy in heart failure (HF). The aim of the current study was to assess cardiac sympathetic activity in HF patients with and without DM.; RESEARCH DESIGN AND METHODS: Patients with severe HF (n = 75), with (n = 37) and without DM (n = 38), and 14 diabetic patients with normal cardiac function underwent (123)I meta-iodobenzylguanidine scintigraphy from which early and late heart-to-mediastinum (H/M) ratios were calculated. Clinical, echocardiographic, and biochemical data were measured.; RESULTS: DM compared with non-DM patients showed significantly lower early (1.65 ± 0.21 vs. 1.75 ± 0.21; P < 0.05) and late H/M ratios (1.46 ± 0.22 vs. 1.58 ± 0.24; P < 0.03). Early and late H/M were significantly higher in DM patients without HF (2.22 ± 0.35 and 1.99 ± 0.24, respectively) than HF patients with (P < 0.0001) and without (P < 0.0001) DM. In HF patients, an inverse correlation between early or late H/M ratio and hemoglobin A1c (HbA1c) (Pearson = -0.473, P = 0.001; Pearson = -0.382, P = 0.001, respectively) was observed. In DM, in multivariate analysis, HbA1c and ejection fraction remained significant predictors of early H/M; HbA1c remained the only significant predictor of late H/M. No correlation between early or late H/M and HbA1c was found in non-DM patients.; CONCLUSIONS: Diabetic patients with HF show lower cardiac sympathetic activity than HF patients not having DM or than DM patients with a similar degree of autonomic dysfunction not having HF. HbA1c correlated with the degree of reduction in cardiac sympathetic activity.
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(308 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
22 Records (22 escludendo Abstract e Conferenze). Impact factor totale: 64.748 (64.748 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 71.729 (71.729 escludendo Abstract e Conferenze).
ibb.cnr.it